Orano Med is a clinical-stage biotechnology subsidiary of the Orano Group focused on developing targeted alpha therapies for cancer using the radioisotope lead-212. The company conducts independent and partnered programs, including collaborations with Sanofi, Roche and Molecular Partners. It maintains research, development and manufacturing capabilities in France and the United States, with a new headquarters and scientific centre opened in Villejuif, France, in 2026.
Orano Med is constructing the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, France, the first industrial-scale plant dedicated to thorium-228 production as a precursor for lead-212 therapies. In 2026 the European Investment Bank provided a €125 million credit line to support this infrastructure and related expansion.
Official website: oranomed.com
chemXplore tracks active investment projects involving Orano Med, across sectors such as Basic Chemicals, Biobased & Circular, and Polymers.
Orano Med's role is mapped on each — as Owner, Operator, and Developer.
